Medicinal Treatment of Elderly Psoriasis Patients before and after Entering a Nursing Home
Standard
Medicinal Treatment of Elderly Psoriasis Patients before and after Entering a Nursing Home. / Petersen, Jana; Garbe, Claudia; Wolf, Sandra; Stephan, Brigitte; Augustin, Matthias; Hagenström, Kristina.
In: HEALTHCARE-BASEL, Vol. 10, No. 9, 1730, 08.09.2022.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Medicinal Treatment of Elderly Psoriasis Patients before and after Entering a Nursing Home
AU - Petersen, Jana
AU - Garbe, Claudia
AU - Wolf, Sandra
AU - Stephan, Brigitte
AU - Augustin, Matthias
AU - Hagenström, Kristina
PY - 2022/9/8
Y1 - 2022/9/8
N2 - Psoriasis (PS) is a chronic inflammatory skin disease, and it increasingly appears also in the elderly population. There is a rising interest in drug therapy for PS, especially for people receiving care in nursing homes (NH). Which PS-related drugs are prescribed in the time before nursing home admission (NHA), and to what extent does the supply of drugs change after NHA? Which specialties prescribe PS-related drugs? Statutory health insurance data were examined for people with PS, aged ≥ 65 years, who were newly admitted to a NH in the period 2011–2014 and observed for one year before and after NHA. Changes in prescription prevalence (pre-post comparison) were examined for significant differences. Prescriptions of PS-relevant drugs were measured by defined daily dose and stratified according to the prescribing specialist group. The analysis included 718 insured persons with PS (76.2% female, mean age 83.3 years). Systemic therapeutics played a minor role (pre: 2.6% vs. post: 2.1%) in drug therapy. Topical steroids had a high share of about 40% in the pre–post comparison. Overall, the proportion of people with PS who received treatment remained at a comparable level before and after NHA. A structured assessment of the skin is crucial, specifically in people with cognitive impairment.
AB - Psoriasis (PS) is a chronic inflammatory skin disease, and it increasingly appears also in the elderly population. There is a rising interest in drug therapy for PS, especially for people receiving care in nursing homes (NH). Which PS-related drugs are prescribed in the time before nursing home admission (NHA), and to what extent does the supply of drugs change after NHA? Which specialties prescribe PS-related drugs? Statutory health insurance data were examined for people with PS, aged ≥ 65 years, who were newly admitted to a NH in the period 2011–2014 and observed for one year before and after NHA. Changes in prescription prevalence (pre-post comparison) were examined for significant differences. Prescriptions of PS-relevant drugs were measured by defined daily dose and stratified according to the prescribing specialist group. The analysis included 718 insured persons with PS (76.2% female, mean age 83.3 years). Systemic therapeutics played a minor role (pre: 2.6% vs. post: 2.1%) in drug therapy. Topical steroids had a high share of about 40% in the pre–post comparison. Overall, the proportion of people with PS who received treatment remained at a comparable level before and after NHA. A structured assessment of the skin is crucial, specifically in people with cognitive impairment.
U2 - 10.3390/healthcare10091730
DO - 10.3390/healthcare10091730
M3 - SCORING: Journal article
C2 - 36141342
VL - 10
JO - HEALTHCARE-BASEL
JF - HEALTHCARE-BASEL
SN - 2227-9032
IS - 9
M1 - 1730
ER -